This webinar provides a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.
A pivotal part of the molecular diagnostics innovation chain that is often overlooked is the relation between critical component suppliers, test manufacturers, and end users. This webinar addresses the development and utility of an innovative multiplex application for detection of Zika, dengue and chikungunya in mosquitos, enabling communities to reduce infection rates by vector control and prevent unnecessary infections and subsequent treatments.
Dr. Jana Kent, Senior Research Scientist from Co-Diagnostics (CoDx), will introduce the company’s CoPrimer technology, which provides flexibility in multiplex assay design without cross-reactivity or non-specific amplification (i.e. primer dimers). She shares insights on the development process of the Zika, dengue and chikungunya test and highlight best practices when working with critical component suppliers and end users.
Next, Ryan Lusty, General Manager of the Magna Mosquito Abatement District in Utah, discusses the implementation of this test in his county and how it impacted healthcare outcomes. Ryan discusses the importance of same-day test results for vector control, as opposed to waiting several days for state lab results.
Joseph Featherstone from CoDx wraps up by addressing the importance of partnership for the success of innovation, development, and commercialization of molecular diagnostics and will present opportunities for new research and commercial applications.